| Literature DB >> 27144645 |
Loïc Epelboin1,2, Renaud Blondé3, Abdourahim Chamouine4, Alexandra Chrisment4, Laure Diancourt5, Nicolas Villemant6, Agnès Atale4, Claire Cadix7, Valérie Caro5, Denis Malvy8, Louis Collet7.
Abstract
INTRODUCTION: Human angiostrongyliasis (HA) is a neurological helminthic disease caused by the lung worm Angiostrongylus cantonensis. It is suspected in the combination of travel or a residence in an endemic area and eosinophilic meningitis. In Mayotte, an island in the Indian Ocean, cases are rare but regular. The main objective of our study was to describe the epidemiological and diagnosis clues of HA in Mayotte. The secondary objectives were to evaluate the contribution of Real-Time Polymerase Chain Reaction (RT- PCR) for the diagnosis of HA, delineate the characteristics of the local transmission and ascertain the presence of A. cantonensis in Achatina fulica, the potential vector of the disease.Entities:
Mesh:
Year: 2016 PMID: 27144645 PMCID: PMC4856411 DOI: 10.1371/journal.pntd.0004635
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Flow chart of the study.
Ac: Angiostrongylus cantonensis; CSF: Cerebrospinal fluid; PCR: Polymerase Chain Reaction. * Eosinophilic meningitis: ≥ 10 eosinophils /mm3 in CSF or ≥10% WBC). ** Meningitis: ≥ 10 WBC in CSF.
Fig 2Amplification curves of six patients positive by Polymerase Chain Reaction and the positive control.
Characteristics of the 14 children with nervous angiostrongyliasis and comparison with the 3 main available paediatric series in the literature.
| Variable | Mayotte, 2015 (n = 14) | Taiwan, 1991 (n = 82) [ | Thailand, 2013 (n = 19) [ | Jamaica, 2014 (n = 6) [ |
|---|---|---|---|---|
| Male gender, N (%) | 11 (78.5) | 38 (46.3) | 15 (78.9) | 4 (66.6) |
| Season | Rainy season | Mostly summer, rainy | Summer | Winter |
| Exposure to intermediate host, N (%) | 5/12 (41.7) Contact with | 71 (87) Contact with | 13 (68.4) Ingestion of freshwater snail | - |
| Incubation period, days | 13.2 (mean) | 22 (median) | ||
| Age (year) | 0.8 (0.5–14) | ~5 (0.8–14) | 12 (4–14) | 1.5 (1–8) |
| Age ≤ 24 month old | 13 (92.9%) | 26/82 (31.7) | - | - |
| Duration of symptoms before admission (days) | 7 (1–28) | - | - | - |
| Temperature (°C) | 38.1 (37.3–39.4) | - | - | - |
| Fever ≥ 38°C, N (%) | 11 (78.5) | 75 (91.5) | 15 (78.9) | 6 (100) |
| Digestive symptoms, N (%) | 10 (71.4) | - | 12 (63.2) | 2 (33.3) |
| Vomiting, N (%) | 3/10 (30.0) | 51 (62.2) | - | - |
| Neurological symptoms, N (%) | 13 (92.9) | - | - | 5 (83.3) |
| Encephalitis signs, N (%) | 8 (57.1) | 25 (30.5) | 0 | 1 (16.7) |
| Dysfunction of cranial nerves, N (%) | 6 (42.9) | 25 (30.5) | 6 (31.6) | 2 (33.3) |
| Seizure, N (%) | 4 (28.6%) | - | - | 0 |
| Axial hypotonia, N (%) | 3 (21.4%) | - | - | 0 |
| Abnormal cerebellar signs, N (%) | 0 (0) | 2 (10.5) | 3 (50) | |
| Hyperesthesia, N (%) | 0 (0) | - | 0 | 0 |
| Headaches, N (%) | 2 (14.3%) | - | 19 (100) | 2 (33.3) |
| Neck stiffness, N (%) | 2 (14.3%) | - | 13 (68.4) | 1 (16.7) |
| Normal brain imaging | 7/12 (58.3%) | 9/16 (56.3) | - | - |
| Enlargement of brain ventricles | 5/12 (41.7%) | 3/16 (18.8) | - | - |
| Cerebral atrophy | 5/12 (41.7%) | - | - | - |
| C-reactive protein (mg/L) | 13.5 (1–225) | - | - | - |
| Blood eosinophilia (/mm3) | 2400 (100–8400) | - | - | - |
| Blood eosinophilia (%) | 14.7 (1–31.8) | - | 20 (5–48) | - |
| Eosinophilia ≥ 1000/mm3 | 13/14 (92.9) | - | - | - |
| Eosinophilia ≥ 10% | 12/14 (85.7) | 69 (84.1) | - | - |
| White cell count in CSF (/mm3) | 340 (54–1500) | - | 637 (87–2610) | 244 (80–640) |
| White cell count ≥ 100/mm3 | 11/14 (78.6) | 76 (92.6) | - | |
| Eosinophilia in CSF (/mm3) | 194 (3–690) | - | - | 14 (11–20) |
| Eosinophilia in CSF (%) | 48 (5–76) | 62.2 (51–90) | 58 (31–95) | - |
| CSF glucose (mmol/L) | 2.3 (1.1–3.5) | - | 3.8 (1.9–13.3) | - |
| Protein level in CSF (g/L) | 0.75 (0.2–1.2) | - | 0.45 (0.26–1.14) | - |
| Protein level > 0.45 g/L | 10/14 (71.4) | 41/67 (61.2%) | - | - |
| 4/10 (40%) | 34 (41.5) | - | - | |
| Real time PCR in CSF | 9/10 (90%) | NR | - | - |
| Worm recovery in CSF (%) | 0 | 25 (30.5) | 0 | 2 |
| One month mortality rate | 2/14 (14.3%) | 4/82 (4.9) | 0 (0) | 0 (0) |
| One month neurological sequelae | 3/12 (25%) | - | - | 2/6 (3.6) |
| One year mortality | 5/14 (35.7%) | - | - | 0 (0) |
| One year neurological sequelae | 3/7 (42.8%) | - | - | 2/6 (3.6) |
* Median, range
CSF: Cerebro-spinal fluid; RT PCR: Real-Time Polymerase Chain reaction
Characteristics of the 14 patients with Angiostrongylus cantonensis infection.
| Case | sexe | Age (month) | Reported contact with mollusk | Duration of symptoms before admission (days) | neurological symptoms | Digestive symptoms | Eosinophil count in blood (/mm3 and %) | CRP (mg/L) | Eosinophil count in CSF (/mm3 and %) | Glucvose level in CSF | Protein level in CSF | Angiostr ilus serodiagnosisIFI Acute/Convalescent phase | Ac RT PCR in CSF | Brain CT-scan | Brain MRI | Treatment | Status 1 month after admission | Status 1 year after admission | Neurocognitive sequelae |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 9 | No | 13 | Axial hypotonia/Seizure | - | 5300 (33,3) | 152 | 690 (46) | 1,7 | 1,2 | - | Normal | - | Albendazole/Ivermectin | Alive | Alive | None | |
| 2 | F | 12 | S-il | 7 | Encephalitis/Dysfunction of cranial nerves | Yes, unspecified | 2600 (22,6) | 17 | 26 (48) | 1,1 | 0,7 | positive (34,6) | Ventricular dilatation / Cerebral Atrophy | - | Albendazole/Flubendazole/ivermectine and corticosteroids | Deceased | Deceased | - | |
| 3 | M | 7 | No | 15 | Axial hypotonia/Headaches | Yes, unspecified | 3200 (15,8) | 4,3 | 144 (40) | 2,4 | 0,8 | positive (33,8) | Normal | - | Ivermectin/Mebendazole and corticosteroids | Alive | Alive | Unknown | |
| 4 | M | 8 | No | 7 | Encephalitis/Dysfunction of cranial nerves | No | 3000 (14) | 10 | 3 (5) | 3,1 | 0,3 | positive (31,8) | Ventricular dilatation / Cerebral Atrophy | - | Ivermectin/Mebendazole and corticosteroids | Deceased | Deceased | - | |
| 5 | M | 9 | No | 7 | Encephalitis Dysfunction of cranial nerves | Anorexia | 100 (1) | 44,5 | 230 (72) | 2,1 | 0,8 | positive (29,5) | Ventricular dilatation / Cerebral Atrophy | - | Albendazole and corticosteroids | Alive | Deceased | - | |
| 6 | M | 9 | S-il | 7 | Encephalitis/Seizure | Anorexia | 2300 (13) | 2 | 100 (40) | 2,8 | 0,9 | - | Ventricular dilatation / Cerebral Atrophy | - | Acetazolamid/Ivermectin/Mebendazole and corticosteroids | Alive | Alive | Psychomotor retardation/epilepsy | |
| 7 | F | 10 | Slug | 1 | Axial hypotonia/intracranial hypertension | Yes, unspecified | 1500 (15,4) | 5,5 | 207 (66) | 3,4 | 0,2 | positive (38,7) | Normal | - | Ivermectin/Mebendazole | Alive | Alive | Psychomotor retardation | |
| 8 | F | 11 | No | 15 | Encephalitis Dysfunction of cranial nerves/Seizure | Anorexia/abdomi-l pain | 2000 (12,1) | 73 | 38 (70) | 1,4 | 0,5 | - | Ventricular dilatation Cerebral Atrophie/hydrocéphalie externe, hyperhémie méningée | - | Ivermectin and corticosteroids | Alive | Deceased | - | |
| 9 | M | 10 | S-il | 1 | Seizure | No | 2000 (16) | 6,2 | 210 (56%) | 3,5 | 0,4 | - | negative | Normal | - | Corticosteroids | Alive | Alive | None |
| 10 | M | 24 | S-il | 15 | Headaches | -useas and vomits | 2500 (13.2) | <5 | 180 (45) | 2,2 | 0.73 | Positive/- | positive (35,9) | Normal | Small scattered hemorrhagic foci (subarachnoid hemorrhage sequellae) | Albendazole and corticosteroids | Alive | Alive | None |
| 11 | M | 168 | - | 28 | None | Vomits/Abdomi-l pain | 5300 (31.2) | <5 | 300 (40) | 2,7 | 0.80 | negative | positive (30,5) | - | - | Albendazole | Alive | Alive | Psychomotor retardation |
| 12 | M | 10 | No | 1 | Hemiparesis/Meningeal syndrome | No | 8400 (31.8) | 225 | 494 (76) | 2,1 | 0.77 | negative | positive (31,9) | Normal | - | Albendazole/Ivermectin | Alive | Alive | None |
| 13 | M | 21 | No | 5 | Dysfunction of cranial nerves/meningeal syndrome | Vomits/Abdomi-l pain | 2000 (17.3) | 18 | 25 (12) | 2,8 | 0.28 | - | positive (32,8) | - | Normal | Albendazole and corticosteroids | Alive | Alive | None |
| 14 | M | 13 | - | - | Dysfunction of cranial nerves | Diarrheoa | 1000 (8) | 46,5 | 504 (56) | 1,7 | 1 | - | - | - | - | - | Alive | Deceased | - |
CSF: Cerebro-spinal fluid; RT PCR: Real-Time Polymerase Chain reaction, CT-scan: computerized tomography scan; CRP: C-Reactive Protein
Comparison of dead and alive children 1 year after A. cantonensis infection.
| Variable | Alive (n = 9) | Deceased (n = 5) | p |
|---|---|---|---|
| Male gender | 8 (88.9%) | 3 (60%) | 0.2 |
| Age (month) | 10 (9–168) | 11 (8–13) | 0.6 |
| Age ≤ 12 month old | 6 (66.7%) | 3 (60%) | 0.8 |
| Symptoms ≥ 7 days before admission | 5 (55.6%) | 4 (80%) | 0.1 |
| Fever (T°≥38°C) | 5/8 (62.5%) | 3/4 (75%) | 1 |
| Digestive symptoms | 5 (62.%) | 3 (60%) | 0.9 |
| Seizure | 3 (33.3%) | 1 (20%) | 0.6 |
| Encephalitis signs | 5 (55.6%) | 4 (80%) | 0.3 |
| Dysfunction of cranial nerves | 1 (16.7%) | 5 (100%) | 0.001 |
| Abnormal brain imaging | 2 (22.2%) | 4 (80%) | 0.04 |
| C-reactive protein (mg/L) | 5.9 (1–225) | 44.5 (17–73) | 0.3 |
| Blood eosinophilia (/mm3) | 2400 (1500–8400) | 2000 (100–3000) | 0.3 |
| Blood eosinophilia ≥ 2500/mm3 | 4 (44.4%) | 2 (40%) | 1 |
| White cell count in CSF (/mm3) | 388 (213–1500) | 54 (54–320) | 0.16 |
| White cell count in CSF > 300/mm3 | 7 (77.8%) | 2(40%) | 0.16 |
| Red cell count in CSF > 50/mm3 | 3 (33.3%) | 2 (40) | 0.8 |
| Eosinophilia in CSF >200/mm3 | 5 (55.6%) | 2 (40%) | 0.6 |
| Eosinophilia in CSF >50% | 3 (33.3%) | 3 (60%) | 0.3 |
| CSF glucose level < 2 mmol/L | 2 (22.2%) | 4 (80%) | 0.04 |
| Protein level in CSF > 0.6 g/L | 6 (66.7%) | 3 (60%) | 0.8 |
| Treatment with albendazole | 5 (55.6%) | 2/4 (50%) | 0.8 |
| Treatment with ivermectin | 4 (57.1%) | 3/4 (75%) | 0.3 |
| Treatment with corticosteroids | 5 (55.6%) | 4/4 (100%) | 0.1 |
* Median, minimum, maximum
** p calculated with Fisher’s exact test for categorical variables and with Mann-Whitney Test for continual variables
¤ Variables with significant differences between the two groups
CSF: Cerebro-spinal fluid;
Fig 3Map of the island of Mayotte representing the number and location of occurrence of the cases of angiostrongyliasis and the pluviometry curves.
Figure 3 was created using Illustrator CS5 (Adobe Systems, Inc.).
Fig 4Monthly repartition of the cases and average pluviometry.
Number of Achatina fulica (African Giant Snail) positive to Angiostrongylus cantonensis with real time PCR and number of collected snails in the place of residence of every sick child.
| Village | Real time PCR | CT |
|---|---|---|
| Cavani | 0/5 | - |
| Kaweni | 0/5 | - |
| Pamandzi | 0/5 | - |
| Acoua | 0/5 | - |
| Passamainty | 0/5 | - |
| Poroani | 0/5 | - |
| Mtsamboro | 2/8 | 22,2/39,4 |
| Mtsapéré | 1/11 | 21,0/ |
| Chiconi | 1/5 | 24,9/ |
| Bandraboua | 1/5 | 26,4/ |
| Bouyouni | 1/5 | 24,8/ |
Real time PCR: Real-Time Polymerase Chain Reaction; CT: threshold cycle